Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and 
early Alzheimer's disease from bioptic olfactory mucosa.

Pellkofer, H.; Ihler, F.; Weiss, B. G.; Trothe, J.; Kadavath, H.; Chongtham, M.; Kunadt, M.; Riedel, D.; Lornsen, F.; Wilken, P.; Bartels, C.; Hirschel, S.; Russo, S. G.; Stransky, E.; Trojan, L.; Schmidt, B.; Mandelkow, E.; Zweckstetter, M.; Canis, M.; Schneider, A.

doi:10.1007/s00406-018-0955-6

Item

ITEM ACTIONSEXPORT

Add to Basket

Please note that a newer version of this item is available:
https://pure.mpg.de/pubman/item/item_3008847_4

DetailsSummary

Released

Journal Article

Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimer's disease from bioptic olfactory mucosa.

MPS-Authors

/persons/resource/persons16093

Zweckstetter, M.
Research Group of Protein Structure Determination using NMR, MPI for biophysical chemistry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Pellkofer, H., Ihler, F., Weiss, B. G., Trothe, J., Kadavath, H., Chongtham, M., et al. (2018). Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimer's disease from bioptic olfactory mucosa. European Archives of Psychiatry and Clinical Neuroscience, (in press). doi:10.1007/s00406-018-0955-6.

Cite as: https://hdl.handle.net/21.11116/0000-0002-7DEE-7

Abstract

Alzheimer's disease (AD) pathology precedes the onset of clinical symptoms by several decades. Thus, biomarkers are required to identify prodromal disease stages to allow for the early and effective treatment. The methoxy-X04-derivative BSC4090 is a fluorescent ligand which was designed to target neurofibrillary tangles in AD. BSC4090 staining was previously detected in post-mortem brains and olfactory mucosa derived from AD patients. We tested BSC4090 as a potential diagnostic marker of prodromal and early AD using olfactory mucosa biopsies from 12 individuals with AD, 13 with mild cognitive impairment (MCI), and 10 cognitively normal (CN) controls. Receiver-operating curve analysis revealed areas under the curve of 0.78 for AD versus CN and of 0.86 for MCI due to AD versus MCI of other causes. BSC4090 labeling correlated significantly with cerebrospinal fluid levels of tau protein phosphorylated at T181. Using NMR spectroscopy, we find that BSC4090 binds to fibrillar and pre-fibrillar but not to monomeric tau. Thus, BSC4090 may be an interesting candidate to detect AD at the early disease stages.